Compare Gilead Sciences, Inc. (GILD) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nerdwallet Inc — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Nerdwallet Inc trades at $9.91 (market cap $625.17M). The key difference: Gilead Sciences, Inc. is far larger — about 291.8× Nerdwallet Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Nerdwallet Inc for 45 Days on average.
| GILD | NRDS | |
|---|---|---|
Market Cap | $182.40B | $625.17M |
Volume | 4,469,821 | 1,321,316 |
Sector | Health | Media |
52-Week High | $155.80 | $15.93 |
52-Week Low | $116.74 | $7.58 |
Typical Hold Time | 111 Days | 45 Days |
Enterprise Value | $205.46B | $539.47M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.
Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
